A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Smith, Rafael (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date11/05/23 → 11/05/25

Keywords

  • clinical trial
  • epilepsy
  • encephalopathy